Company Filing History:
Years Active: 1999
Title: Dibyendu N. SenGupta: Innovator in Antiviral Biotechnology
Introduction
Dibyendu N. SenGupta is a notable inventor based in Shaker Heights, OH, recognized for his contributions in the field of antiviral biotechnology. With two patents to his name, his work emphasizes the innovative potential of transgenic plants and the molecular mechanisms behind interferon-induced enzymes.
Latest Patents
SenGupta's recent patents focus on "Antiviral transgenic plants, vectors, cells and methods," particularly highlighting the isolated 2-5A-dependent RNases, an interferon-induced enzyme. This enzyme is activated by 5'-phosphorylated, 2',5'-linked oligoadenylates (2-5A) and plays a crucial role in the molecular mechanisms of interferon action and the control of RNA stability within mammalian cells. His patents disclose several aspects, including recombinant human 2-5A-dependent RNase produced in vitro, which binds to an activating affinity matrix, demonstrating ribonuclease activity. Additionally, the analysis of mRNA levels in cells treated with interferon and cycloheximide showcases the induction of 2-5A-dependent RNase expression. His work also includes findings related to the binding properties of recombinant and naturally occurring forms of the enzyme, emphasizing its similarity to RNase E, an enzyme implicated in mRNA stability control in E. coli. The patents further cover recombinant nucleotide sequences, vectors, cells, and antiviral plants designed to express sequences with the capability to inhibit viral replication.
Career Highlights
Dibyendu N. SenGupta is affiliated with The Cleveland Clinic Foundation, a prestigious institution known for its commitment to medical research and innovation. His research is critical in understanding the antiviral properties and biotechnological applications of RNases, contributing significantly to the field.
Collaborations
Among his notable collaborators is Robert H. Silverman, a respected figure in the area of molecular biology and biotechnology. Their work together has led to advancements that enhance the understanding of antiviral mechanisms and the development of new therapeutic strategies.
Conclusion
Dibyendu N. SenGupta stands out as a prominent inventor in antiviral research, with his patents paving the way for innovative solutions in plant biotechnology and RNA stability control. His collaboration with esteemed professionals and his dedication to research at The Cleveland Clinic Foundation underline the impact of his work on modern medicine and biotechnology.